Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | HBB | P68871 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1755976 | 0.84 | HSD11B1 (0.41) | HSD11B1DHFRRAB9AMEN1KMT2A | |
| SCHEMBL563008 | 0.83 | HSD11B1 (0.38) | HSD11B1DHFRRAB9AMEN1KMT2A | |
| SCHEMBL20004827 | 0.83 | HSD11B1 (0.41) | HSD11B1DHFRRAB9AMEN1KMT2A | |
| SCHEMBL2017636 | 0.82 | HSD11B1 (0.40) | HSD11B1DHFRRAB9AMEN1KMT2A | |
| SCHEMBL5535487 | 0.82 | HSD11B1 (0.40) | HSD11B1DHFRCHRNA3RAB9AMEN1 | |
| SCHEMBL30900827 | 0.82 | HSD11B1 (0.43) | HSD11B1DHFRRAB9AMEN1KMT2A | |
| SCHEMBL6680451 | 0.82 | HSD11B1 (0.43) | HSD11B1DHFRRAB9AMEN1KMT2A | |
| SCHEMBL3453117 | 0.82 | DHFR (0.42) | HSD11B1DHFRRAB9AMEN1KMT2A | |
| SCHEMBL2198944 | 0.81 | MEN1 (0.49) | CHRNA3RAB9AMEN1KMT2ANPC1 | |
| SCHEMBL16554271 | 0.81 | HSD11B1 (0.44) | HSD11B1DHFRRAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-11-30 | — | — | US | disclosed |
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| CN-110790789-B | Dioxolane analogues of uridine for use in the treatment of cancer | 美迪维尔公司 | 2023-05-12 | — | — | CN | disclosed |
| CN-110804072-B | Dioxolane analogues of uridine for use in the treatment of cancer | 美迪维尔公司 | 2023-05-12 | — | — | CN | disclosed |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2023-04-20 | — | — | US | disclosed |
| US-11447511-B2 | Dioxolane analogues of uridine for the treatment of cancer | MEDIVIR AB (SE) | 2022-09-20 | — | — | US | disclosed |
| EP-3572410-B1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2022-07-20 | — | — | EP | disclosed |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | MEDIVIR AB (SE) | 2021-02-25 | — | — | US | disclosed |
| US-7456218-B2 | 3-(4-benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-25 | — | — | US | disclosed |
| US-7456218-B2 | 3-(4-benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-25 | — | — | US | disclosed |
| US-7456218-B2 | 3-(4-benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-25 | — | — | US | disclosed |
| US-20070149608-A1 | 3-(4-Benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149608-A1 | 3-(4-Benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20070149608-A1 | 3-(4-Benzyloxyphenyl) propanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
| US-20060258722-A1 | Condensed ring compound | TAKEDA PHARMACEUTICAL COMPANY., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| EP-1697339-A1 | 3-(4-BENZYLOXYPHENYL)PROPANOIC ACID DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
| EP-1630152-A1 | CONDENSED RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2006-03-01 | — | — | EP | disclosed |
| WO-2005063729-A1 | 3-(4-BENZYLOXYPHENYL)PROPANOIC ACID DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149608-A1 | 3-(4-Benzyloxyphenyl) propanoic acid derivatives | GPR119, GPR55, GLP1R | HSD11B1 636/4885DHFR 4660/4885CHRNA3 880/4885 |
| US-20230117570-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NT5C | HSD11B1 757/4885DHFR 29/4885CHRNA3 163/4885 |
| US-20060258722-A1 | Condensed ring compound | GPR119, GLP1R, GCGR | HSD11B1 555/4885DHFR 4416/4885CHRNA3 1044/4885 |
| US-20210054008-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | HSD11B1 893/4885DHFR 34/4885CHRNA3 156/4885 |
| US-11447511-B2 | Dioxolane analogues of uridine for the treatment of cancer | ADORA3, DUT, NTPCR | HSD11B1 893/4885DHFR 34/4885CHRNA3 156/4885 |
| US-20230257382-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TRPC5, TRPC1, GOT1 | HSD11B1 353/4885DHFR 449/4885CHRNA3 3683/4885 |
| US-20230382931-A1 | DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER | ADORA3, DUT, NTPCR | HSD11B1 893/4885DHFR 34/4885CHRNA3 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.